Gossamer Bio, Inc. GOSS
Regular-session close
After hours · Nov 20, 4:00 PM ET
- YTD
- -95.68%
- 1 year
- -95.69%
5D +0.25 (+2.31%)
- Market cap
- 65.57M
- Revenue (ttm)
- 53.29M
- Profit margin
- -235.00%
- EPS (ttm)
- -42.41
- Shares out
- 488.85M
- Forward P/E
- -0.69
- YTD return
- -95.68%
- 1-year return
- -95.69%
- Volume
- 191.43K
- Avg volume
- 266.06K
- Open
- 11.02
- Previous close
- 11.23
- Day's range
- 10.65 – 11.60
- 52-week range
- 8.43 – 303.20
- Beta
- 2.00
- Price target
- 132.48 (+1135.8%)
Key statistics
- 50-day average
- 13.50
- 200-day average
- 78.36
- Enterprise value
- 52.65M
- Price / sales
- 98.44
- Revenue growth
- -19.60%
- Free cash flow
- -29.76M
- Total cash
- 57.03M
- Total debt
- 40.07M
- Short % of float
- 0.21%
Fundamental scorecard
3 of 25 checks passed on GOSS’s reported financials
3of 25 checks passed
- Value 0 of 5
- Growth 2 of 5
- Profitability 0 of 5
- Financial health 1 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 4, 2026 | Sep 30, 2026 | -3.69 | — | — | — |
| Aug 13, 2026 | Jun 30, 2026 | -9.87 | -0.20 | +9.67 | +97.97% |
| May 18, 2026 | Mar 31, 2026 | -13.60 | -0.20 | +13.40 | +98.53% |
| Mar 18, 2026 | Dec 31, 2025 | -16.00 | -0.21 | +15.79 | +98.69% |
| Nov 6, 2025 | Sep 30, 2025 | -15.20 | -16.80 | -1.60 | -10.53% |
| Aug 11, 2025 | Jun 30, 2025 | -14.40 | -0.17 | +14.23 | +98.82% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 14, 2026 | Piper Sandler | main | Overweight | Overweight |
| Jul 28, 2026 | Leerink Partners | up | Market Perform | Outperform |
| Jul 27, 2026 | HC Wainwright & Co. | reit | Buy | Buy |
| Jun 25, 2026 | HC Wainwright & Co. | main | Buy | Buy |
| May 26, 2026 | HC Wainwright & Co. | reit | Buy | Buy |
| May 19, 2026 | Barclays | main | Underweight | Underweight |
About Gossamer Bio, Inc.
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary hypertension and pulmonary arterial hypertension in the United States. The company develops GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. The company was incorporated in 2015 and is headquartered in San Diego, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- gossamerbio.com
News
Does Gossamer Bio (GOSS) Have the Potential to Rally 659.56% as Wall Street Analysts Expect? Gossamer Bio Files Prospectus Related To The Proposed Resale Or Other Disposition By The Selling Securityholders Of Up To 1,697,363 Shares Of Common Stock
Gossamer Bio Analysts Slash Their Forecasts Following Q3 Results Piper Sandler Maintains Overweight on Gossamer Bio, Lowers Price Target to $96
Wedbush Maintains Neutral on Gossamer Bio, Lowers Price Target to $32
Gossamer Bio Q3 EPS $(7.36) Misses $(3.68) Estimate, Sales $38.431M Beat $12.148M Estimate
Your note
Sign in to keep a note on GOSS — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ARANDA RICHARD | Officer | Stock Award(Grant) | Jan 1, 2026 | 465,645 |
| CHRISTIAN WAAGE | Officer | Stock Award(Grant) | Jan 1, 2026 | 882,175 |
| GIRAUDO BRYAN M. | Chief Operating Officer | Stock Award(Grant) | Jan 1, 2026 | 869,747 |
| HASNAIN FAHEEM | Chief Executive Officer | Stock Award(Grant) | Jan 1, 2026 | 6,245,870 |
| MILLIGAN SANDRA | Director | Purchase | Aug 18, 2025 | 58,050 |
| PETERSON CARYN | Officer | Stock Award(Grant) | Jan 1, 2026 | 259,333 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Shaw D.E. & Co., Inc. | 8.38% | 40,959,285 | 439.49M | Jun 29, 2026 |
| 683 Capital Management LLC | 8.02% | 39,198,868 | 420.60M | Jun 29, 2026 |
| DeepCurrents Investment Group, LLC | 7.70% | 37,665,073 | 404.15M | Jun 29, 2026 |
| Context Capital Management, LLC | 5.92% | 28,946,459 | 310.60M | Jun 29, 2026 |
| Worth Venture Partners, Llc | 5.12% | 25,017,881 | 268.44M | Jun 29, 2026 |
| AQR Capital Management, LLC | 3.20% | 15,629,993 | 167.71M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 1.41% | 6,910,934 | 74.15M | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 0.46% | 2,243,305 | 24.07M | Jun 29, 2026 |
| iShares Trust-iShares Biotechnology ETF | 0.31% | 1,501,116 | 16.11M | Jun 29, 2026 |
| SCHWAB STRATEGIC TRUST-Schwab U.S. Small-Cap ETF | 0.20% | 986,826 | 10.59M | May 30, 2026 |
| VANGUARD SCOTTSDALE FUNDS-Vanguard Russell 2000 Index Fund | 0.20% | 977,030 | 10.48M | May 30, 2026 |
| VANGUARD WORLD FUND-Vanguard Health Care Index Fund | 0.11% | 541,950 | 5.82M | May 30, 2026 |
